Diagnostic value of serum IL‐6 level in monoclonal gammopathies

Summary. The serum level of IL-6 was reported to reflect disease severity in patients with multiple myeloma. We used a specific radioimmunoassay to measure the level of IL-6 in 239 serum samples in which a monoclonal gammopathy was identified for the first time. The same sample was used for the measurement of serum C reactive protein and serum albumin. Then, an inventory of clinical and biological features allowed us to classify these patients into five groups: monoclonal gammopathy of undetermined significance (MGUS: 128), multiple myeloma (MM:66), Waldenstrom's macroglobulinaemia (WM:27), non-Hodgkin's lymphoma (NHL: 11) and chronic lymphocytic leukaemia (CLL: 7). The number of patients with serum IL-6 (S-IL-6) level >0.335 ng/ml (upper limit in normal sera) was significantly higher in the MM group (35%; Confidence Interval (CI) 23.5–46.5) compared with the MGUS group (15%; CI 8.8–21.2). The distribution of S-IL-6 levels was also significantly different between the groups (Mann-Whitney test: P 50% (P<0.05) and stages II and III in the Durie & Salmon staging system (P< 0.005). The S-IL-6 level was also related to light chain component excretion in urine (P<0.01) and M component serum level for IgA (P<0.01). In patients with MGUS, the S-IL-6 level correlated with serum CRP level (P<0.05). serum lactate dehydrogenase (P< 0.05) and serum ferritin (P < 0.01). We conclude that the S-IL-6 level is a marker of high tumour burden in multiple myeloma. However, S-IL-6 level can be increased in patients with MGUS in relation to inflammatory parameters. Therefore the S-IL-6 level does not demonstrate high predictive value for the diagnosis of MM in patients with newly identified monoclonal gammopathy.